Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Institut de Cancérologie Gustave Roussy

6 abstracts

Abstract
Biomarker analysis of zanzalintinib in clear cell renal cell carcinoma from STELLAR-001.
Org: APHP Hôpital Européen Georges Pompidou and Université Paris Cité, Charles University and Thomayer University Hospital, Institut de Cancérologie Gustave Roussy,
Abstract
The RAINBO MMRd-GREEN trial (GCIG/DGOG/ENGOT-EN142): A phase III trial on the addition of adjuvant durvalumab to radiotherapy in patients with high-risk MMRd endometrial cancer.
Org: Leiden University Medical Center, Institut de Cancérologie Gustave Roussy, London Regional Cancer Program Ontario, Tübingen University Hospital, Fondazione Policlinico Universitario A. Gemelli IRCCS,
Abstract
The diagnostic landscape of HRD testing based on cross-sectional survey of physicians and molecular biologists conducting testing (INDICATOR ONE).
Org: Texas Oncology, Sarah Cannon Research Institute (SCRI), AstraZeneca Pharmaceuticals LP, ICON Commercial Solutions, Institut de Cancérologie Gustave Roussy,
Abstract
CCTG EN10: A phase II study of tailored adjuvant therapy in POLE-mutated and p53-wildtype/NSMP early-stage endometrial cancer (EC)—RAINBO BLUE and TAPER.
Org: BCCA, Princess Margaret - University Health Network, Saskatchewan Health Authority, Centre hospitalier de l'Université de Montréal, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada,
Abstract
Safety analysis by UGT1A1 status of TROPHY-U-01 cohort 1, a phase 2 study of sacituzumab govitecan (SG) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PT)-based chemotherapy and a checkpoint inhibitor (CPI).
Org: Institut de Cancérologie Gustave Roussy, Université Paris-Saclay, Gustave Roussy, Villejuif, France, Yale School of Medicine, University of California Irvine, Centre Léon Bérard,
Abstract
Efficacy of sacituzumab govitecan (SG) in locally advanced (LA) or metastatic urothelial cancer (mUC) by trophoblast cell surface antigen 2 (Trop-2) expression.
Org: Institut de Cancérologie Gustave Roussy, Villejuif, France, France, Perlmutter Cancer Center at NYU Langone Health Medical Center, New York, NY,